Kathleen N. Moore, MD
Mirvetuximab soravtansine (IMGN853) demonstrated a favorable toxicity profile and encouraging clinical activity in patients with epithelial ovarian cancer, according to a pooled analysis of phase I expansion cohorts that was presented at the 2017 ASCO Annual Meeting.
at ASCO, lead study author Kathleen Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discussed the potential of mirvetuximab soravtansine in patients with epithelial ovarian cancer.
OncLive: Can you provide an overview of the analyses you presented?
Mirvetuximab soravtansine is the first antibody-drug conjugate in a pivotal phase III trial for patients with ovarian cancer. The abstract that I presented was a pooled analysis of the phase I expansion cohorts. There are 3 expansion cohorts.
... to read the full story